je.st
news
Home
› The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia
The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia
2013-02-04 07:00:00| drugdiscoveryonline News Articles
The Medicines Company and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia
Tags: the
of
form
company
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||